Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Thorac Cardiovasc Surg ; 70(8): 623-629, 2022 12.
Article in English | MEDLINE | ID: mdl-35038756

ABSTRACT

OBJECTIVE: Surgery of acute aortic dissection using the frozen elephant trunk (FET) can be complicated when the origin of the left subclavian artery (LSA) is dissected and sacrifice by ligation is a viable option. However, the LSA is supposed to play a role in neuroprotection as a major collateral. We, therefore, analyzed our results of LSA sacrifice in this cohort. METHODS: We identified a total of 84 patients from our prospectively collected database who underwent FET repair of acute aortic dissection between October 2009 and April 2018. LSA was sacrificed in 19 patients (22.6%). Results were analyzed and compared with regard to neurological outcomes. RESULTS: New postoperative stroke was seen in two patients (2.4%) and spinal cord injury in three patients (3.6%) overall, none in the LSA-sacrifice group. We observed a temporary neurological deficit in five patients (6.0%) overall, none in the LSA-sacrifice group. None of the patients developed acute ischemia of the left arm. Only two patients (12.5%) came back for carotid-subclavian artery bypass due to exertion-induced weakness of the left arm 3 to 4 months after the initial surgery. In-hospital mortality was 15.5% overall, with no difference between groups. CONCLUSION: LSA sacrifice was not associated with elevated postoperative risk of either central or spinal neurological injury. Thus, it can facilitate FET repair of acute aortic dissection in selected cases when the left subclavian origin cannot be preserved. Carotid-subclavian artery bypass became necessary in only a small fraction of these patients and can be performed as a second-stage procedure.


Subject(s)
Aortic Aneurysm, Thoracic , Aortic Dissection , Blood Vessel Prosthesis Implantation , Endovascular Procedures , Humans , Subclavian Artery/surgery , Stents , Treatment Outcome , Aorta, Thoracic/surgery , Aortic Aneurysm, Thoracic/surgery , Retrospective Studies , Endovascular Procedures/methods
2.
J Interv Cardiol ; 30(2): 156-162, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28247436

ABSTRACT

OBJECTIVE: The purpose of this study is to provide a systematic review of currently available data about the percutaneous trans-coronary-venous mitral annuloplasty with the Carillon Mitral Contour System. METHOD: A systematic literature search was conducted using the common medical and scientific databases. The documented parameters included among others grade of mitral regurgitation (MR), vena contracta (VC), effective regurgitant orifice area (EROA), 6 minute-walk-test (6MWT), NYHA-classification, and Quality of Life (QoL) at baseline, 30 days and in the long-term follow-up. RESULTS: The exact total number of successfully implantations with available data remains unclear because so many publications are either of the same institution or study group, or they present overlapping results. Reduction of functional mitral regurgitation (FMR) was associated with significant inverse left-ventricular (LV)) remodeling, improvement in 6MWT, QoL and NYHA-class during the 12-month follow-up. In almost half of the enrolled patients, the Carillon System could not be implanted or had to be removed due to coronary compromission. Adverse advent rate (AE) ranged between 2.8-39%. CONCLUSIONS: Results with regard to reduction of MR and inverse LV remodeling have been remarkable. Indication and selection criteria for suitable patients, the expected complications, and the long-term results with regard to survival and quality of life still remain unclear. The available results do not establish superiority of the Carillon Mitral Contour System and support the lack of a clear benefit. The approach with the Carillon Mitral Contour System should be limited to participants of prospective and randomized trials.


Subject(s)
Mitral Valve Annuloplasty/instrumentation , Mitral Valve Insufficiency/surgery , Aged , Female , Humans , Male , Middle Aged , Mitral Valve Annuloplasty/adverse effects , Treatment Outcome
3.
J Interv Cardiol ; 28(1): 69-75, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25689550

ABSTRACT

OBJECTIVES: The authors investigated safety and efficacy of the MitraClip-System (MCS) using a systematic analysis. BACKGROUND: The safety and efficacy of the MCS continues to be debated, and randomized trials are still lacking. METHOD: A systematic literature search was conducted using common medical and scientific databases. The following kinds of data were obtained: at baseline, 30 days, 6 and 12 month post-procedure. For safety and efficacy mortality-rate (survival), mitral regurgitation <2+ (MR), adverse event rate (AE), NYHA class and reoperation-rate were documented. A meta-analysis with quantitative summary was performed. RESULTS: Twenty-six studies including 3821 patient's who were treated with MCS, were analyzed. Weighted mean age was 73.9 ± 2.3 years and LogEuroScore was 25.2 ± 6.0%. Post-procedural MR<2+ was achieved in 86.4% and 66.3% of the patients were in NYHA class I/II within 30 days, AE-rate was 18.3%, mortality-rate was 2.8% and reoperation-rate was 3.5%. Freedom from MR>3 + -4 was 80.2% (80.1%), from NYHA III/IV was 78.6% (66.1%) and freedom from death was 82.6% (87.8%) and from reoperation 95.6% (88.6%) at 6 and 12 month. CONCLUSION: Based on the analysis of the current literature treatment with MCS is associated with good short-term success and low mortality. MCS is safe and effective for patients with limited surgical options. The results are comparable with open mitral valve repair (oMVR) but patients are markedly older and have a higer risk profile than patients who undergo oMVR. Prospective randomized controlled trials are warranted to determine potential AEs, device durability and long-term follow-up.


Subject(s)
Heart Valve Prosthesis , Mitral Valve Insufficiency/surgery , Mitral Valve/surgery , Humans , Patient Outcome Assessment
4.
Vasc Endovascular Surg ; 47(4): 261-6, 2013 May.
Article in English | MEDLINE | ID: mdl-23427286

ABSTRACT

PURPOSE: Recently, vascular endostapling systems were developed to achieve better sealing at the proximal neck of the aneurysm and to prevent endograft migration. The purpose of this study was to provide a systematic review about the current state and possible options of vascular endostapling systems. RESULTS: No randomized controlled trials were published. The results showed that the use of an endostaple system considerably reduced the rates of endoleaks type 1a and endograft migration. Regarding the use of endostaples in different types of endografts, only a few results were available. CONCLUSION: The results are not conclusive. With endostaple systems, patients with difficult anatomic features and high risk can potentially be treated. These systems might reduce the high reintervention rates after endovascular aneurysm repair. Controlled randomized trials with larger number of patients are warranted with endostapling use in primary endograft implantation and for use in reintervention for late endoleaks or endograft migrations.


Subject(s)
Aortic Aneurysm, Thoracic/surgery , Blood Vessel Prosthesis Implantation/instrumentation , Blood Vessel Prosthesis , Endovascular Procedures/instrumentation , Surgical Staplers , Surgical Stapling/instrumentation , Animals , Blood Vessel Prosthesis Implantation/adverse effects , Endoleak/etiology , Endoleak/prevention & control , Endovascular Procedures/adverse effects , Equipment Design , Foreign-Body Migration/etiology , Foreign-Body Migration/prevention & control , Humans , Prosthesis Design , Prosthesis Failure , Surgical Stapling/adverse effects , Treatment Outcome
5.
J Vasc Surg ; 55(6): 1826-8, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22277688

ABSTRACT

We present a silicon sheet for temporary wound covering and gradual wound closure after open fasciotomy. Fasciotomy was performed in a total of 70 limbs with compartment syndrome (CS). The main etiology of CS was predominantly vascular. All patients were treated with a silicon sheet to cover the soft tissue defect and gradually reapproximate the skin margins. In 53% of the patients, a delayed final wound closure was achieved after a mean of 11.9 days. This method allows final closure of fasciotomy wounds without scar contractures, marginal necrosis, infection, or significant pain.


Subject(s)
Compartment Syndromes/surgery , Decompression, Surgical/methods , Fasciotomy , Occlusive Dressings , Silicones/therapeutic use , Wound Closure Techniques/instrumentation , Wound Healing , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Time Factors , Treatment Outcome , Young Adult
6.
Echocardiography ; 26(5): 508-12, 2009 May.
Article in English | MEDLINE | ID: mdl-19452606

ABSTRACT

OBJECTIVES: Hydrotin-C is a bacterial cellulose consisting of 90% of physiological solution. The cellulose pad is smooth and elastic and cannot be torn, and is therefore suitable for use on any local skin condition. The aim of this study was to evaluate the image quality (IQ) and transducer pressure of Hydrotin-C-Pads as a solid coupling agent compared with standard coupling gel. METHODS: To date, transthoracic echocardiography has been performed in 51 patients (ongoing study) using standard coupling gel and Hydrotin-C-Pads. The IQ was categorized as follows: 1 = excellent, 2 = good, 3 = poor, 4 = inadequate. All patients were questioned about the transducer pressure, which was categorized as: 0 = less, 1 = equal, 2 = more. The body mass index (BMI) was documented for all patients. RESULTS: The IQ was very good with Hydrotin-C-Pads. The IQ was better in 84% of all patients. In patients with a BMI of over 25 and in patients with a BMI of over 30, Hydrotin-C-Pads was also better compared with standard gel. The transducer pressure was lower in 33 patients. CONCLUSIONS: Hydrotin-C-Pads can be used as a solid ultrasonic coupling agent. Because of the consistent thickness of the coupling zone, the IQ seems to be better for Hydrotin-C-Pads compared with standard coupling gel. The transducer presser is lower, and these pads are easy to apply and are reusable and reduce the burden of clean-up after treatment.


Subject(s)
Bandages, Hydrocolloid , Cellulose/administration & dosage , Image Enhancement/methods , Lung Diseases/diagnostic imaging , Ultrasonography/methods , Aged , Female , Humans , Male , Reproducibility of Results , Sensitivity and Specificity
7.
Int J Cardiol ; 136(2): 227-8, 2009 Aug 14.
Article in English | MEDLINE | ID: mdl-18625528

ABSTRACT

BACKGROUND: This study was designed to examine plasma concentrations of BNP and its correlations to the perioperative course in patients' cardiopulmonary bypass (CPB). METHODS: Sixty-five patients with coronary artery disease (CAD) undergoing CPB were examined. Pre, intra and postoperative BNP values and hemodynamic parameters were measured. RESULTS: The BNP peak correlated neither with any hemodynamic parameters, with the duration of aortic cross-clamping (AXCL), of the operation or with CBP-time, nor with the use of catecholamines. BNP values were significantly higher with the perioperative use of aprotinin. CONCLUSION: These results confirm that the metabolism and biological activity of BNP may differ following CPB. An additional reason for increased postoperative BNP values might be the use of aprotinin.


Subject(s)
Aprotinin/administration & dosage , Cardiac Surgical Procedures , Cardiopulmonary Bypass , Hemostatics/administration & dosage , Natriuretic Peptide, Brain/blood , Aged , Humans , Middle Aged
8.
Scand Cardiovasc J ; 41(5): 339-44, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17852779

ABSTRACT

OBJECTIVE: The pharmacologic properties of Brain natriuretic peptide make it a favourable substance to use after cardiac operations. The goal of this study was to evaluate the effect of BNP following cardio-pulmonary bypass (CPB). METHOD: Nineteen pigs were operated on using CPB. One group received BNP and the control group received placebo. A 30-minute ischemic episode was simulated. Following declamping, BNP was administered by an IV bolus, followed by an infusion for 60 minutes. Hemodynamic and clinical chemistry parameters were documented, as well as the amount of catecholamines. RESULTS: The Cardiac output and Cardiac Index in the BNP group were significantly higher 60 minutes after ending CPB. Seven of ten animals in the control group needed catecholamines at the end of the experiment, whereas none of the animals in the BNP group did at this juncture. Creatine kinase and Lactate were significantly lower. CONCLUSION: BNP is a well-tolerated agent that could present a new treatment option for heart failure following cardiac surgery. Hemodynamics are greatly improved with almost no need for pharmacological support.


Subject(s)
Cardiopulmonary Bypass , Heart Failure/prevention & control , Myocardial Ischemia/physiopathology , Natriuretic Agents/administration & dosage , Natriuretic Peptide, Brain/administration & dosage , Animals , Catecholamines , Creatine Kinase , Female , Hemodynamics , Lactic Acid , Male , Myocardial Ischemia/complications , Natriuretic Agents/therapeutic use , Natriuretic Peptide, Brain/therapeutic use , Postoperative Period , Swine , Time Factors
9.
Echocardiography ; 24(5): 457-63, 2007 May.
Article in English | MEDLINE | ID: mdl-17456063

ABSTRACT

OBJECTIVE: Reduction ascending aortoplasty (RAA) is a controversial procedure. Agreement has not yet been made regarding the indication for surgery and surgical technique. The goal of this study was to examine the long-term outcome of RAA without external support, and to compare the accuracy of transthoracic echocardiographic with computed tomographic (CT) measurements. Of particular interest was whether the important elastic properties of the aorta, the Windkessel function, is preserved following reduction aortoplasty of the ascending aorta without external wrapping. METHODS: Ninety-eight patients with dilation of the ascending aorta underwent reduction aortoplasty with concomitant cardiac procedures. Fifty-four patients were available for follow-up. Measurement of the ascending aortic diameter was performed prior to and directly following surgery, and 37 months postoperatively (range: 10-96 months). Both echocardiography and CT imaging were performed. The elastic properties of the ascending aorta were determined by measuring the distension of the ascending aorta during diastole and systole by means of transthoracic echocardiography. Fifteen patients with graft replacement of the ascending aorta were examined, and the control group contained 11 healthy volunteers. RESULTS: The diameter of the ascending aorta was significantly reduced in all patients who had undergone RAA. The change in diameter between diastole and systole was 3 mm in patients with reduction aortoplasty. Patients with graft replacement had a change of only 0.07 cm. There was no relevant increase (2 mm) in diameter at follow-up. Echocardiographic and CT measurements of the aortic diameter did not differ. CONCLUSIONS: RAA without external wrapping shows good long-term results in patients with a dilated ascending aorta who underwent concomitant cardiac procedures. Echocardiography is very accurate in measuring the ascending aortic diameter, which makes it a cost-effective diagnostic tool. Moreover, ascending aortoplasty without external wrapping preserves the important elastic properties, namely the Windkessel function. Follow-up of the cardiac function and aortic diameter can be performed easily and precisely in the outpatient setting.


Subject(s)
Aortic Diseases/physiopathology , Aortic Diseases/surgery , Blood Vessel Prosthesis Implantation , Adult , Aged , Aged, 80 and over , Analysis of Variance , Aorta , Aortic Diseases/diagnostic imaging , Case-Control Studies , Diastole , Dilatation, Pathologic/diagnostic imaging , Dilatation, Pathologic/physiopathology , Dilatation, Pathologic/surgery , Echocardiography , Elasticity , Female , Follow-Up Studies , Germany , Humans , Male , Middle Aged , Postoperative Period , Systole , Time Factors , Tomography, X-Ray Computed , Treatment Outcome
10.
Ann Thorac Surg ; 83(3): 1047-53, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17307457

ABSTRACT

BACKGROUND: Moderate aneurysms of the ascending aorta that are associated with other cardiac diseases are frequently encountered by cardiac surgeons. Reduction ascending aortoplasty (RAA) provides an elegant technique to handle these aneurysms; however, its applicability is still under debate. Many surgeons reject RAA because of an assumed redilatation. We investigated the postoperative stability of RAA without external support and whether the elastic property of the aorta (Windkessel function) remains preserved. METHODS: From 1996 to 2003, 97 patients (mean age, 67 years) underwent RAA without external stabilization in our institution as a concomitant procedure during cardiac surgery. The diameter of the ascending aorta was measured before and directly after surgery, as well as postoperatively from 10 to 96 months (median, 32 months). RESULTS: The mean preoperative diameter was 4.55 +/- 0.43 cm, while the early postoperative diameter measured 3.53 +/- 0.44 cm. Fifty-four of the 97 patients were available for follow-up. The mean diameter measured at follow-up was 3.68 +/- 0.41 cm. The mean increase was 0.17 +/- 0.27 cm. There was no relevant difference in redilatation between patients with follow-up of more than 60 months or less. Furthermore, the aortic wall demonstrated a near normal diastolic-systolic augmentation assessed by echocardiography. CONCLUSIONS: Reduction ascending aortoplasty without external stabilization is a reliable treatment for patients suffering from a moderately enlarged ascending aorta who require cardiac surgery for other indications. In these cases, with the technique described, a redilatation can be prevented and the Windkessel function of the ascending aorta remains preserved.


Subject(s)
Aorta/physiopathology , Aorta/surgery , Aortic Aneurysm/physiopathology , Aortic Aneurysm/surgery , Vascular Surgical Procedures/methods , Vasodilation , Adult , Aged , Aged, 80 and over , Aorta/diagnostic imaging , Aortic Aneurysm/diagnosis , Aortography , Compliance , Echocardiography , Female , Follow-Up Studies , Humans , Male , Middle Aged , Survival Analysis , Tomography, X-Ray Computed
11.
Clin Sci (Lond) ; 112(5): 315-24, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17073825

ABSTRACT

The critical phase during cardiosurgical procedures is weaning the diseased heart from the ECC (extracorporeal circulation). Post-ischaemic heart failure sometimes requires the administration of inotropic and/or vasconstrictive agents. The natriuretic peptides influence pre- and after-load through their natriuretic, diuretic and vasodilating actions. To date, there are only a few reports describing the therapeutic effect of BNP (brain natriuretic peptide) administration during cardiosurgical procedures. The aim of the present study was to evaluate the effect of BNP administration following ECC in an animal model. Surgery was performed on 20 pigs using ECC. A 30-min ischaemic episode was simulated. Following de-clamping, BNP was administered to the BNP group (n=10) by an i.v. (intravenous) bolus at 0.3 microg x kg(-1) of body weight x min(-1), followed by an infusion at a rate of 0.015 microg x kg(-1) of body weight x min(-1) for 60 min. The animals in the control group (n=10) received a saline solution instead of BNP. Haemodynamic and clinical chemistry parameters as well as the amount of catecholamines that were required were measured. All of the animals in the BNP group had a significantly better cardiac output and cardiac index at the end of the experiment. Seven out of 10 animals from the control group required catecholamines, whereas only one animal from the BNP group did. Creatine kinase levels were significantly lower in the BNP group. Systemic vascular resistance was markedly lower in the BNP group. In conclusion, administration of BNP is highly effective in treating post-ischaemic heart failure following ECC. Haemodynamics are greatly improved, and there is almost no need for pharmacological support.


Subject(s)
Extracorporeal Circulation/adverse effects , Heart Failure/drug therapy , Intraoperative Care/methods , Natriuretic Peptide, Brain/therapeutic use , Vasodilator Agents/therapeutic use , Animals , Cardiac Output/drug effects , Cardiac Surgical Procedures , Creatine Kinase/blood , Drug Administration Schedule , Drug Evaluation, Preclinical , Female , Heart Failure/blood , Heart Failure/etiology , Heart Failure/physiopathology , Male , Natriuretic Agents/therapeutic use , Natriuretic Peptide, Brain/administration & dosage , Natriuretic Peptide, Brain/blood , Swine , Vascular Resistance , Ventricular Function, Left/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...